source
- Novo Nordisk may secure more favorable terms under Medicare’s Bridge obesity drug programNovo Nordisk and Eli Lilly have been profiting from a Medicare pilot that caps obesity drug prices for seniors at $245 a month. Recent analysis suggests Novo could negotiate an even better arrangem…
- Roche presents positive Phase 2 results for enicepatide in overweight and obese type 2 diabetes patientsRoche has released new data from a Phase 2 trial of enicepatide, a peptide acquired from Carmot Therapeutics, focusing on overweight or obese adults with type 2 diabetes. The trial met its primary…